ReviewCancers2025
Artificial Intelligence and New Technologies in Melanoma Diagnosis: A Narrative Review.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multimodal Non-Invasive Skin Imaging in Dermatology: Current Modalities, Clinical Applications, and Future Integration.Diagnostics (Basel, Switzerland) · 2026Review
- Artificial intelligence in three-dimensional total-body photography for skin cancer surveillance.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Melanoma is among the most lethal forms of skin cancer, where early and accurate diagnosis significantly improves patient survival. Traditional diagnostic pathways, including clinical inspection and dermoscopy, are constrained by interobserver variability and limited access to expertise. Between 2020 and 2025, advances in artificial intelligence (AI) and medical imaging technologies have substantially redefined melanoma diagnostics. This narrative review synthesizes key developments in AI-based approaches, emphasizing the progression from convolutional neural networks to vision transformers and multimodal architectures that incorporate both clinical and imaging data. We examine the integration of AI with non-invasive imaging techniques such as reflectance confocal microscopy, high-frequency ultrasound, optical coherence tomography, and three-dimensional total body photography. The role of AI in teledermatology and mobile applications is also addressed, with a focus on expanding diagnostic accessibility. Persistent challenges include data bias, limited generalizability across diverse skin types, and a lack of prospective clinical validation. Recent regulatory frameworks, including the European Union Artificial Intelligence Act and the United States Food and Drug Administration's guidance on adaptive systems, are discussed in the context of clinical deployment. The review concludes with perspectives on explainable AI, federated learning, and strategies for equitable implementation in dermatological oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.